Raloxifene identified as potential inhibitor for pediatric acute myeloid leukemia via ANP32B targeting
Raloxifene inhibits the proliferation of pediatric acute myeloid leukemia by targeting the ANP32B gene.
Asset / Drug
Drug and asset intelligence for Raloxifene with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.